Cellectar Inc., a Madison pharmaceutical company working on cancer-fighting drugs, has merged with a publicly traded Boston-area firm, Novelos Therapeutics Inc. The transaction essentially grafts Cellectar's research onto the upper management of Novelos. Read full Journal Sentinel story
here.
